Back to results
US 2016/0237106 A1Published application
4'-azido substituted nucleoside derivatives as inhibitors of ebola virus rna replication
AssigneeRiboscience LLC
InventorsMark Smith, Klaus G. Klumpp
Life of this patent
Estimating the term…
Abstract
The application discloses compounds of Formula I wherein the variable substituents are as defined herein. The compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I are useful for the treatment of diseases mediated by Filoviruses such as Ebolavirus.
Claims16
A method of treating a disease mediated by Ebolavirus, Marburgvirus, or other Filovirus, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I
- wherein:
- Y is H or P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, —OP(═O)(OH)OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- Ry, and Rz are each independently H, Me, OH or F;
- X is O or S;
- and
- Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- or a pharmacologically acceptable salt thereof.
21 more elements
A compound of Formula II,
- wherein:
- Base is guanine;
- Y is P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R4 together form CH2;
- and
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- with the proviso that the compound is not cyclohexyl ((((2R,3R,4R,5R)-5-(2-amino-6-oxo-3,6-dihydro-9H-purin-9-yl)-2-azido-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate;
- or a pharmacologically acceptable salt thereof.
20 more elements
A method for treating an infection with a Filovirus related negative strand RNA virus from the Bornaviridae, Rhabdoviridae, Paramyxoviridae, Arenaviridae, Bunyaviridae or Orthomyxoviridae families, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I
- wherein:
- Y is H or P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, —OP(═O)(OH)OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- Ry, and Rz are each independently H, Me, OH or F;
- X is O or S;
- and
- Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- or a pharmacologically acceptable salt thereof.
21 more elements
A method for treating an infection with a Filovirus related positive strand RNA virus from the Coronaviridae, Picornaviridae, Flaviviridae or Togaviridae families, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I
- wherein:
- Y is H or P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, —OP(═O)(OH)OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- Ry, and Rz are each independently H, Me, OH or F;
- X is O or S;
- and
- Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- or a pharmacologically acceptable salt thereof.
21 more elements
A method for inhibiting replication of a Filovirus in a cell comprising administering to the cell a compound of Formula I
- wherein:
- Y is H or P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, —OP(═O)(OH)OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- Ry, and Rz are each independently H, Me, OH or F;
- X is O or S;
- and
- Base is uracil, cytosine, guanine, adenine, thymine, or heterocycloalkyl, each of which may optionally be substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- or a pharmacologically acceptable salt thereof.
21 more elements
A compound of Formula II,
- wherein:
- Base is adenine;
- Y is P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- and
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- with the proviso that the compound is not isopropyl ((((2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-azido-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate;
- or a pharmacologically acceptable salt thereof.
20 more elements
A compound of Formula II,
- wherein:
- Base is cytosine;
- Y is P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- and
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- with the proviso that the compound is not isopropyl ((((2S,3S,4S,5S)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(((R)-1-isopropoxy-1-oxopropan-2-yl)amino)phosphoryl)-L-alaninate or isopropyl ((((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1 (2H)-yl)-2-azido-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate;
- or a pharmacologically acceptable salt thereof.
20 more elements
A compound of Formula II,
- wherein:
- Base is uracil;
- Y is P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- and
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- with the proviso that the compound is not isopropyl ((((2S,3S,4S,5S)-2-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(((R)-1-isopropoxy-1-oxopropan-2-yl)amino)phosphoryl)-L-alaninate, isopropyl ((((2R,3R,4S,5R)-2-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate, or isopropyl ((((2R,3R,4R,5R)-2-azido-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate;
- or a pharmacologically acceptable salt thereof.
20 more elements
A compound of Formula II,
- wherein:
- Base is thymine;
- Y is P(═X)(R′)(R);
- R is O—R1 or NHR1′;
- R1′ is —C(R2a)(R2b)C(═O)OR3;
- R′ is N(R4)C(R2a)(R2b)C(═O)OR3, —OP(═O)(OH)OH, or —OR3;
- R1 is H, lower haloalkyl, or aryl, wherein aryl is phenyl or naphthylenyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halo, lower haloalkyl, —N(R1a)2, acylamino, —SO2N(R1a)2, —C(═O)R1b, —SO2(R1c), —NHSO2(R1c), nitro, cyano, or R1″;
- each R1a is independently H or lower alkyl;
- each R1b is independently —OR1a or —N(R1a)2;
- each R1c is lower alkyl;
- each R2a and R2b is independently H, lower alkyl, —(CH2)rN(R1a)2, lower hydroxyalkyl, —CH2SH, —(CH2)S(O)pMe, —(CH2)nNHC(═NH)NH2, (1H-indol-3-yl)methyl, (1H-indol-4-yl)methyl, —(CH2)mC(═O)R1b, aryl and aryl lower alkyl, wherein aryl is optionally substituted with one or more hydroxy, lower alkyl, lower alkoxy, halo, nitro or cyano;
- m is 0, 1, or 2;
- n is 1, 2, or 3;
- p is 1 or 2;
- r is 1 or 2;
- or R2a is H and R2b and R4 together form (CH2)n;
- each R3 is independently H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, wherein phenyl and phenyl lower alkyl are optionally substituted with lower alkoxy;
- or R3 and R1″ together form CH2;
- and
- each R4 is independently H, lower alkyl;
- or R2b and R4 together form (CH2)3;
- or a pharmacologically acceptable salt thereof.
19 more elements
A compound selected from the list consisting of:
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-(O-1-naphthyl-N-(S)-1-(i2,2-dimethylpropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-(O-1-naphthyl-N-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-(O-1-phenyl-N-(S)-1-(hexoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-(O-1-naphthyl-N-(S)-1-(cyclopentoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-{N,N′-bis[(S)-1-(benzyloxycarbonyl)ethyl]phosphorodiamidate};
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-{N,N′-bis[(S)-1-(hexoxycarbonyl)ethyl]phosphorodiamidate};
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-{N,N′-bis[(S)-1-(cyclopentoxycarbonyl)ethyl]phosphorodiamidate};
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-uridine;
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-O-[bis(4-methoxyphenoxy)phosphinyl]uridine;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-phenyl-N-(S)-1-(ethoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-phenyl-N-(S)-1-(neopentoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-1-naphthyl-N-(S)-1-(2,2-dimethylpropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-1-naphthyl-N-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-1-naphthyl-N-(S)-1-(3,3-dimethybutoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-1-naphthyl-N-(S)-1-(cyclohexoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-{N,N′-bis[(S)-1-(2,2-dimethylpropoxycarbonyl)ethyl]phosphorodiamidate};
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-{N,N′-bis[(S)-1-(hexoxycarbonyl)ethyl]phosphorodiamidate};
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-{N,N′-bis[(S)-1-(cyclohexoxycarbonyl)ethyl]phosphorodiamidate};
- 4′-Azido-2′-deoxy-2′-fluoro-5′-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-cytidine;
- 4′-Azido-2′-deoxy-2′-fluoro-5′-O-[bis(4-methoxyphenoxy)phosphinyl]cytidine;
- 4′-Azido-2′-deoxy-2′-fluorocytidine-3′,5′-cyclic phosphoric acid isopropyl ester;
- 4′-Azido-2′-deoxy-2′-fluoroadenosine-5′-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluoroadenosine-5′-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluoroadenosine-5′-{N,N′-bis[(S)-1-(isopropoxycarbonyl)ethyl]phosphorodiamidate;
- 4′-Azido-2′-deoxy-2′-fluoro-5′-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-adenosine;
- 4′-Azido-2′-deoxy-2′-fluoro-5′-O-[bis(4-methoxyphenoxy)phosphinyl]adenosine;
- 4′-Azido-2′-deoxy-2′-fluoroadenosine-3′,5′-cyclic phosphoric acid isopropyl ester;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-(O-1-naphthyl-N-(S)-1-(hexoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-(O-1-naphthyl-N-(S)-1-(isobutoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-(O-1-naphthyl-N-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;
- 3′-Acetyl-4′-azido-2′-deoxy-2′-fluoroguanosine-5′-(O-1-naphthyl-N-(S)-1-(isobutoxycarbonyl)ethyl phosphoramidate;
- 3′-Acetyl-4′-azido-2′-deoxy-2′-fluoroguanosine-5′-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 3′-Acetyl-4′-azido-2′-deoxy-2′-fluoroguanosine-5′-(O-2-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-{N,N′-bis[(S)-1-(isopropoxycarbonyl)ethyl]phosphorodiamidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-{N,N′-bis[(S)-1-(isobutoxycarbonyl)ethyl]phosphorodiamidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-{N,N′-bis[(S)-1-(cyclohexoxycarbonyl)ethyl]phosphorodiamidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-{N,N′-bis[(S)-1-(cyclopentoxycarbonyl)ethyl]phosphorodiamidate;
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-5′-{N,N′-bis[(S)-1-(benzyloxycarbonyl)ethyl]phosphorodiamidate;
- 4′-Azido-2′-deoxy-2′fluoro-5′-O-(2-oxido-4-H-1,3,2-benzodioxaphosphorin-2-yl)-guanosine;
- 4′-Azido-2′-deoxy-2′-fluoro-5′-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
- 3′-Acetyl-4′-azido-2′-deoxy-2′-fluoro-5′-O-[bis(4-methoxyphenoxy)phosphinyl]guanosine;
- and
- 4′-Azido-2′-deoxy-2′-fluoroguanosine-3′,5′-cyclic phosphoric acid isopropyl ester.
45 more elements
A compound selected from the group consisting of:
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azido-2′-deoxy-2′-fluorouridine-5′-{N,N′-bis[(S)-1-(isopropoxycarbonyl)ethyl]phosphorodiamidate};
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- and
- 4′-Azido-2′-deoxy-2′-fluorocytidine-5′-{N,N′-bis[(S)-1-(isopropoxycarbonyl)ethyl]phosphorodiamidate}.
2 more elements
A compound of Formula I, wherein the compound is 4′-Azidouridine-5′-(O-1-naphthyl-N-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate.
A compound of Formula I, wherein the compound is selected from the group consisting of:
- 4′-Azidouridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azidocytidine-5′-(O-phenyl-N-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;
- 4′-Azidocytidine-5′-(O-phenyl-N-(S)-1-(eisopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azidocytidine-5′-(O-naphthyl-N-(S)-1-(benzyloxycarbonyl)ethyl phosphoramidate;
- 4′-Azidoadenosine-5′-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- 4′-Azidoguanosine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate;
- and
- 4′-Azidoguanosine-5′-(O-1-naphthyl-N-(S)-1-(isopropoxycarbonyl)ethyl phosphoramidate.
5 more elements
Dependencies are inferred from the claim text.